MRD Diagnostics
Our minimal residual disease testing platform enables the precise detection and monitoring of remaining cancer cells after therapy.
What is MRD Diagnostics?
MRD (Minimal Residual Disease) refers to the smallest amounts of cancer cells that may persist in the body after treatment. These cells are often undetectable with conventional imaging methods but can be revealed through minimal residual disease MRD testing using highly sensitive ctDNA assays.
Through continuous minimal residual disease monitoring, clinicians can detect relapse months before it becomes visible on imaging and tailor therapeutic strategies accordingly.
Early Detection
Detect disease recurrence months before it becomes visible through imaging methods, enabling early intervention
Therapy Monitoring
Continuous minimal residual disease monitoring during treatment provides dynamic insights into therapy response and resistance
Risk Stratification
Assess individual relapse risk with precision to personalize follow-up and post-treatment care
Available Tests
LymphoVista
B-Cell Lymphomas
ctDNA test for all B-cell lymphomas including DLBCL, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Burkitt lymphoma, and CNS lymphoma.
LymphoVista HL
Hodgkin Lymphoma
Specifically developed for Hodgkin lymphoma with a modified gene spectrum optimized for HL.
CancerVista - Solid Tumors
Currently available for research use only (RUO)
LIQOMICS is expanding its portfolio with minimal residual disease testing solutions for solid tumors. The CancerVista pipeline aims to enable minimal residual disease monitoring and therapy evaluation for a broad range of cancers.
Planned Tumor Types:
Lung Cancer
NSCLC & SCLC
Breast Cancer
All subtypes
Colorectal Cancer
Colorectal carcinoma
Prostate Cancer
Prostate carcinoma
Ovarian Cancer
Ovarian carcinoma
Pancreatic Cancer
Pancreatic carcinoma
Glioblastoma
CNS tumors
Additional
Additional tumor types in planning
Clinical Applications
After Primary Therapy
Perform minimal residual disease testing after completion of primary therapy to assess treatment response and identify patients at risk of relapse.
During Therapy
Use minimal residual disease MRD testing to monitor disease burden and detect resistance or treatment failure in real time.
Follow-up Care
Enable continuous minimal residual disease monitoring for early relapse detection, often months before imaging results show recurrence.
Clinical Studies
Support clinical research with precise MRD endpoints for therapy evaluation, survival analysis, and personalized medicine approaches.
Vista Technology
Our proprietary Vista technology allows ultra-sensitive ctDNA analysis with tumor-specific gene panels. It detects even the smallest traces of tumor DNA with exceptional accuracy and reproducibility.
High Sensitivity
Detection limits up to 6.69 × 10⁻⁶ for precise MRD detection
Tumor-Specific Panels
Optimized for diverse hematologic and solid tumors
Clinically Validated
Supported by multi-center studies with prognostic significance
RilibÄK Compliant
Adheres to German quality assurance standards
References
1 Schleifenbaum et al. Presentation at European Hematology Association (EHA) Annual Meeting 2024
2 Mattlener et al. Presentation at American Society of Hematology (ASH) Annual Meeting 2024
Interested in MRD Diagnostics?
Contact us for more information about our minimal residual disease testing services or to order one of our available assays.